Abstract
L-3,4-Dihydroxyphenylalanine (L-DOPA), the precursor of dopamine, and bromocriptine, a dopamine D2 receptor agonist, were investigated in haloperidol-induced motor impairments in mice using both catalepsy and pole tests. In catalepsy test, subcutaneous treatment with haloperidol (0.125, 0.25 and 0.5 mg/kg) caused a cataleptic effect in mice in a dose-dependent manner. This cataleptic effect was evident upto 7 hr after haloperidol treatment. In pole test, haloperidol (0.125, 0.25 and 0.5 mg/kg) produced the prolongation of Tturn and TLA as a marker of bradykinesia in mice and the prolongation lasted at least 7 hr after haloperidol treatment. Intraperitoneal co-pretreatment with L-DOPA (400 mg/kg) + carbidopa (10 mg/kg) in mice decreased the catalepsy induced by haloperidol at a dose of 0.125 mg/kg, while co-pretreatment with L-DOPA (200 and 400 mg/kg) + carbidopa (10 mg/kg) dose-dependently decreased the haloperidol (0.125 mg/kg)-induced bradykinesia. The effect of LDOPA + carbidopa in pole test was more pronounced than that in catalepsy test. Intraperitoneal pretreatment with bromocriptine (2 and 4 mg/kg) in mice reduced the catalepsy and bradykinesia produced by haloperidol at a dose of 0.125 mg/kg. The effect of bromocriptine...Continue Reading
References
Dec 1, 1991·Journal of Neurochemistry·Y TasakiM Hirobe
Jan 1, 1990·Psychopharmacology·F Wanibuchi, S Usuda
May 7, 1990·Brain Research·N AraiY Misu
Mar 1, 1989·Pharmacology, Biochemistry, and Behavior·W J Schmidt, M Bubser
Jan 1, 1987·European Neurology·N OgawaY Watanabe
Oct 1, 1988·Behavioral Neuroscience·P R SanbergA B Norman
Sep 1, 1972·The Journal of Pharmacy and Pharmacology·J MajJ Sarnek
Citations
Apr 25, 2012·Psychopharmacology·Ilya D Ionov, Nicholas N Severtsev
Jan 15, 2011·Neurotoxicity Research·Ozlem OzsoyMutay Aslan
May 28, 2005·Neuropharmacology·K OssowskaA Pilc
Jan 5, 2002·Journal of Neuroscience Methods·Pierre O FernagutFrançois Tison
Oct 30, 2001·Behavioural Brain Research·M SedelisJ P Huston
Dec 25, 2002·Neurobiology of Aging·Rumiko KurosakiTsutomu Araki
Apr 21, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·T ArakiY Itoyama
Dec 11, 2013·Neurotoxicity Research·Annalisa Pinna, Micaela Morelli
Dec 27, 2015·Neuropeptides·Harshal A Fegade, Sudhir N Umathe
Jan 17, 2007·Neuroscience·J KoniecznyK Ossowska
Jan 17, 2009·Journal of Neuroscience Methods·Pratibha Mehta LuthraRam Raghubir
Apr 14, 2011·British Journal of Pharmacology·Susan Duty, Peter Jenner
Jul 9, 2011·Neurochemistry International·Ozlem OzsoyMutay Aslan
May 11, 2001·Neuropeptides·V KlusaJ E Wikberg
Aug 22, 2014·Behavioural Pharmacology·Sanjay B KastureElio Acquas
Aug 29, 2017·Rejuvenation Research·Bijay Kumar GuptaSanjula Baboota
Aug 19, 2003·Human Psychopharmacology·Marat G Uzbekov, Eduard Y Misionzhnik
Dec 19, 2017·The European Journal of Neuroscience·Nedjeljka IvicaPer Petersson
Mar 25, 2009·International Journal of Immunopathology and Pharmacology·J KoniecznyM Pokorski
Feb 10, 2019·Tissue & Cell·Nuray AcarAysel Agar
Apr 6, 2021·The European Journal of Neuroscience·Isabelle WakuAmanda R de Oliveira
May 26, 2004·Pharmacology, Biochemistry, and Behavior·Rumiko KurosakiTsutomu Araki